ADMA Biologics, Inc., a biopharmaceutical company headquartered in Ramsey, United States, specializes in the development and commercialization of human plasma and plasma-derived therapeutics aimed at immunity-compromised patients. As a key player in the Health Care sector, specifically within the Biotechnology industry, ADMA Biologics is listed on the Nasdaq exchange and trades in USD.
As of February 23, 2026, the company’s stock closed at $15.52. This price is situated below its 52-week high of $25.67, achieved on April 27, 2025, and above its 52-week low of $13.50, recorded on March 3, 2025. The current market capitalization stands at approximately $3.70 billion USD, reflecting the company’s substantial presence in the biotechnology sector.
In its most recent public disclosure, ADMA Biologics presented at the JPMorgan Healthcare Conference on January 13, 2026. The stock’s valuation metrics include a price-to-earnings (P/E) ratio of 18.96 and a price-to-book (P/B) ratio of 8.89. These figures indicate a moderate premium relative to both earnings and book value, suggesting investor confidence in the company’s growth prospects and financial health.
The stock’s current price is approximately 60% above its 52-week low and 40% below its 52-week high, indicating a moderate upside potential within its recent trading range. The technical profile of ADMA Biologics reveals a stable valuation framework, with an earnings multiple that aligns with sector norms. The price-to-book ratio reflects a valuation that is closer to the company’s asset base, underscoring a balanced approach to growth and asset management.
Overall, ADMA Biologics maintains a strategic focus on advancing its portfolio of plasma-derived therapeutics, positioning itself as a significant contributor to the biotechnology landscape, particularly in addressing the needs of immunity-compromised patients.
